Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 3 (2006), Issue 8 (August)

1. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure.
   BJU Int, 98(2): 353-8. [Abstract] [Full-text]
2. Incidence of cervical cytological abnormalities with aging in the women's health initiative: a randomized controlled trial.
   Obstet Gynecol, 108(2): 410-9. [Abstract] [Full-text]
3. Inappropriate use of antibiotic prophylaxis to prevent infective endocarditis in obstetric patients.
   Obstet Gynecol, 108(2): 280-5. [Abstract] [Full-text]
4. Neuropharmacology and mental health nurse prescribers.
   J Clin Nurs, 15(8): 989-97. [Abstract] [Full-text]
5. Patient self-medication--a change in hospital practice.
   J Clin Nurs, 15(8): 962-70. [Abstract] [Full-text]
6. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung.
   Toxicol Appl Pharmacol, 215(1): 100-8. [Abstract] [Full-text]
7. Effects of long-term hormone treatment and of tibolone on monoamines and monoamine metabolites in the brains of ovariectomised, Cynomologous monkeys.
   J Neuroendocrinol, 18(9): 643-54. [Abstract] [Full-text]
8. Symptomatic hyponatremia during treatment of dehydrating diarrheal disease with reduced osmolarity oral rehydration solution.
   JAMA, 296(5): 567-73. [Abstract] [Full-text]
9. Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma.
   J Natl Cancer Inst, 98(15): 1088-91. [Abstract] [Full-text]
10. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    J Natl Cancer Inst, 98(15): 1036-45. [Abstract] [Full-text]
11. A prospective observational study of a cohort of outpatients with an acute medical event and reduced mobility: incidence of symptomatic thromboembolism and description of thromboprophylaxis practices.
    J Intern Med, 260(2): 168-76. [Abstract] [Full-text]
12. Strategies for optimizing combinations of molecularly targeted anticancer agents.
    Nat Rev Drug Discov, 5(8): 649-59. [Abstract] [Full-text]
13. Risk factors for invasive, early-onset Escherichia coli infections in the era of widespread intrapartum antibiotic use.
    Pediatrics, 118(2): 570-6. [Abstract] [Full-text]
14. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005.
    Pediatrics, 118(2): e534-6. [Abstract] [Full-text]
15. Socioeconomic impact of modern multidisciplinary management of retinoblastoma.
    Pediatrics, 118(2): e331-6. [Abstract] [Full-text]
16. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Pediatrics, 118(2): e315-22. [Abstract] [Full-text]
17. Verified hormone therapy improves episodic memory performance in healthy postmenopausal women.
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn, 13(3): 291-307. [Abstract] [Full-text]
18. Low-level environmental exposure to lead and progressive chronic kidney diseases.
    Am J Med, 119(8): 707.e1-9. [Abstract] [Full-text]
19. Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients.
    Am J Clin Oncol, 29(4): 399-404. [Abstract] [Full-text]
20. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
    Am J Clin Oncol, 29(4): 395-8. [Abstract] [Full-text]
21. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
    Am J Clin Oncol, 29(4): 380-4. [Abstract] [Full-text]
22. Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC).
    Am J Clin Oncol, 29(4): 371-5. [Abstract] [Full-text]
23. Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma.
    Am J Clin Oncol, 29(4): 361-3. [Abstract] [Full-text]
24. Gemcitabine, ifosfamide, and cisplatin combination (GIP) in treatment of patients with locally advanced or metastatic nonsmall cell lung cancer: results of a phase II study.
    Am J Clin Oncol, 29(4): 345-51. [Abstract] [Full-text]
25. Systemic treatment of malignant thymoma: a decade experience at a single institution.
    Am J Clin Oncol, 29(4): 336-44. [Abstract] [Full-text]
26. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.
    Lancet, 368(9534): 489-504. [Abstract] [Full-text]
27. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.
    Lancet, 368(9534): 459-65. [Abstract] [Full-text]
28. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.
    Lancet, 368(9534): 451-8. [Abstract] [Full-text]
29. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
    Blood, 108(4): 1174-82. [Abstract] [Full-text]
30. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
    Blood, 108(4): 1165-73. [Abstract] [Full-text]
31. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis.
    Biomol Eng, 23(4): 171-84. [Abstract] [Full-text]
32. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Arch Pediatr Adolesc Med, 160(8): 778-87. [Abstract] [Full-text]
33. Use of quantitative cultures and reduced duration of antibiotic regimens for patients with ventilator-associated pneumonia to decrease resistance in the intensive care unit.
    Clin Infect Dis, 43: S75-81. [Abstract] [Full-text]
34. In vitro-reassembled plant virus-like particles for loading of polyacids.
    J Gen Virol, 87: 2749-54. [Abstract] [Full-text]
35. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.
    JAMA, 296(6): 679-90. [Abstract] [Full-text]
36. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
    J Clin Oncol, 24(23): 3735-46. [Abstract] [Full-text]
37. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    J Clin Oncol, 24(23): 3747-55. [Abstract] [Full-text]
38. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
    J Clin Oncol, 24(23): 3771-9. [Abstract] [Full-text]
39. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
    J Clin Oncol, 24(23): 3789-98. [Abstract] [Full-text]
40. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
    J Clin Oncol, 24(23): 3726-34. [Abstract] [Full-text]
41. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy.
    J Infect Dis, 194(5): 661-5. [Abstract] [Full-text]
42. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.
    J Infect Dis, 194(5): 612-22. [Abstract] [Full-text]
43. Automated medication error studies with audit supplementation were effectively designed and analyzed by time series.
    J Clin Epidemiol, 59(9): 957-63. [Abstract] [Full-text]
44. Perioperative fluid therapy in children: a survey of current prescribing practice.
    Br J Anaesth, 97(3): 371-9. [Abstract] [Full-text]
45. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
    Cancer Chemother Pharmacol, 58(5): 585-93. [Abstract] [Full-text]
46. A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
    Cancer Chemother Pharmacol, 58(5): 673-80. [Abstract] [Full-text]
47. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Cancer Chemother Pharmacol, 58(5): 692-8. [Abstract] [Full-text]
48. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
    Cancer Chemother Pharmacol, 58(5): 634-9. [Abstract] [Full-text]
49. Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging.
    Cancer Chemother Pharmacol, 58(5): 607-17. [Abstract] [Full-text]
50. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
    Cancer Chemother Pharmacol, 58(5): 601-6. [Abstract] [Full-text]
51. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
    Cancer Chemother Pharmacol, 58(5): 570-6. [Abstract] [Full-text]
52. Crosslinking treatment of progressive keratoconus: new hope.
    Curr Opin Ophthalmol, 17(4): 356-60. [Abstract] [Full-text]
53. Metabolic and skeletal complications of HIV infection: the price of success.
    JAMA, 296(7): 844-54. [Abstract] [Full-text]
54. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.
    JAMA, 296(7): 827-43. [Abstract] [Full-text]
55. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
    JAMA, 296(7): 769-81. [Abstract] [Full-text]
56. Predictors of treatment error for children with uncomplicated malaria seen as outpatients in Blantyre district, Malawi.
    Trop Med Int Health, 11(8): 1147-56. [Abstract] [Full-text]
57. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.
    Int J Radiat Oncol Biol Phys, 66(1): 206-11. [Abstract] [Full-text]
58. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma.
    Int J Radiat Oncol Biol Phys, 66(1): 142-51. [Abstract] [Full-text]
59. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy.
    Int J Radiat Oncol Biol Phys, 66(1): 100-7. [Abstract] [Full-text]
60. A prospective study of reduced-dose three-course CHOP followed by involved-field radiotherapy for patients 70 years old or more with localized aggressive non-Hodgkin's lymphoma.
    Int J Radiat Oncol Biol Phys, 66(1): 217-22. [Abstract] [Full-text]
61. A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.
    Int J Radiat Oncol Biol Phys, 66(1): 201-5. [Abstract] [Full-text]
62. Cell death induced by MPPa-PDT in prostate carcinoma in vitro and in vivo.
    Biochem Biophys Res Commun, 348(2): 413-20. [Abstract] [Full-text]
63. Medicare prescription drug cards: effectiveness for patients with glaucoma.
    Arch Ophthalmol, 124(8): 1175-9. [Abstract] [Full-text]
64. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety.
    Expert Opin Drug Saf, 5(5): 703-18. [Abstract] [Full-text]
65. Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells.
    Br J Cancer, 95(4): 485-95. [Abstract] [Full-text]
66. The experience of physical symptoms among women living with HIV.
    Nurs Clin North Am, 41(3): 395-408, vi. [Abstract] [Full-text]
67. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
    J Natl Cancer Inst, 98(16): 1108-17. [Abstract] [Full-text]
68. Role of ovarian hormones in the regulation of protein metabolism in women: effects of menopausal status and hormone replacement therapy.
    Am J Physiol Endocrinol Metab, 291(3): E639-46. [Abstract] [Full-text]
69. Bovine polymerized hemoglobin versus Hextend resuscitation in a swine model of severe controlled hemorrhagic shock with delay to definitive care.
    Shock, 26(3): 302-10. [Abstract] [Full-text]
70. Primary sciatic nerve lymphoma: a case report and review of the literature.
    J Neurol Neurosurg Psychiatry, 77(9): 1087-9. [Abstract] [Full-text]
71. Hormone treatment gives no benefit against cognitive changes caused by acute sleep deprivation in postmenopausal women.
    Neuropsychopharmacology, 31(9): 2079-88. [Abstract] [Full-text]
72. Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women.
    Neuropsychopharmacology, 31(9): 2065-78. [Abstract] [Full-text]
73. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis.
    Arterioscler Thromb Vasc Biol, 26(9): 2103-9. [Abstract] [Full-text]
74. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma.
    J Clin Oncol, 24(24): 4011-9. [Abstract] [Full-text]
75. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    J Clin Oncol, 24(24): 3997-4002. [Abstract] [Full-text]
76. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    J Clin Oncol, 24(24): 3991-6. [Abstract] [Full-text]
77. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
    J Clin Oncol, 24(24): 3953-8. [Abstract] [Full-text]
78. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
    J Clin Oncol, 24(24): 3946-52. [Abstract] [Full-text]
79. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?
    J Clin Oncol, 24(24): 3939-45. [Abstract] [Full-text]
80. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
    J Clin Oncol, 24(24): 3927-32. [Abstract] [Full-text]
81. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
    J Clin Oncol, 24(24): 3919-26. [Abstract] [Full-text]
82. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
    J Clin Oncol, 24(24): 3912-8. [Abstract] [Full-text]
83. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
    J Clin Oncol, 24(24): 3871-9. [Abstract] [Full-text]
84. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    J Clin Oncol, 24(24): 3844-51. [Abstract] [Full-text]
85. Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
    J Clin Oncol, 24(24): 3838-43. [Abstract] [Full-text]
86. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
    J Clin Oncol, 24(24): 3823-30. [Abstract] [Full-text]
87. Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART).
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 102(3): 318-24. [Abstract] [Full-text]
88. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.
    Lancet, 368(9536): 679-86. [Abstract] [Full-text]
89. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
    J Clin Oncol, 24(24): 3880-6. [Abstract] [Full-text]
90. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    J Clin Oncol, 24(24): 3865-70. [Abstract] [Full-text]
91. Ultrasound-guided hydrostatic reduction of intussusceptions by saline enema: a review of 5218 cases in 17 years.
    Am J Surg, 192(3): 273-5. [Abstract] [Full-text]
92. Discontinuity of chronic medications in patients discharged from the intensive care unit.
    J Gen Intern Med, 21(9): 937-41. [Abstract] [Full-text]
93. Systems biology and combination therapy in the quest for clinical efficacy.
    Nat Chem Biol, 2(9): 458-66. [Abstract] [Full-text]
94. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
    Int Immunopharmacol, 6(10): 1550-9. [Abstract] [Full-text]
95. Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice.
    Behav Brain Res, 173(1): 76-84. [Abstract] [Full-text]
96. Regulatory T cells generated during cytomegalovirus in vitro stimulation of mononuclear cells from HIV-infected individuals on HAART correlate with decreased lymphocyte proliferation.
    Virology, 352(2): 408-17. [Abstract] [Full-text]
97. Selective use of steroid replacement after adrenalectomy: lessons from 331 consecutive cases.
    Arch Surg, 141(8): 771-4; discussion 774-6. [Abstract] [Full-text]
98. Estrogen therapy and cognition: a 6-year single-blind follow-up study in postmenopausal women.
    Neurology, 67(4): 706-9. [Abstract] [Full-text]
99. Outcome in hyperglycemic stroke with ultrasound-augmented thrombolytic therapy.
    Neurology, 67(4): 700-2. [Abstract] [Full-text]
100. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?
     Eur J Haematol, 77(3): 239-44. [Abstract] [Full-text]
101. Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps.
     Biochem Pharmacol, 72(6): 729-38. [Abstract] [Full-text]
102. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
     BJU Int, 98(3): 580-5. [Abstract] [Full-text]
103. High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours.
     BJU Int, 98(3): 519-25. [Abstract] [Full-text]
104. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation.
     Leukemia, 20(9): 1533-8. [Abstract] [Full-text]
105. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study.
     Leukemia, 20(9): 1526-32. [Abstract] [Full-text]
106. Colorectal cancer: screening double-contrast barium enema examination in average-risk adults older than 50 years.
     Radiology, 240(3): 725-35. [Abstract] [Full-text]
107. Antidepressants and youth suicide in New York City, 1999-2002.
     J Am Acad Child Adolesc Psychiatry, 45(9): 1054-8. [Abstract] [Full-text]
108. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.
     Blood, 108(5): 1504-8. [Abstract] [Full-text]
109. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
     Blood, 108(5): 1469-77. [Abstract] [Full-text]
110. Comparison of radiologists and technologists in the performance of air-contrast barium enemas.
     AJR Am J Roentgenol, 187(3): 706-9. [Abstract] [Full-text]
111. A randomized comparison of retention balloon and standard tip rectal catheters in preventing incontinence during double-contrast barium enema.
     AJR Am J Roentgenol, 187(3): 702-5. [Abstract] [Full-text]
112. Cerebral air embolism after intrathoracic anti-cancer drug administration.
     Ann Thorac Surg, 82(3): 1121-3. [Abstract] [Full-text]
113. Intrapleural instillation of autologous blood in the treatment of prolonged air leak after lobectomy: a prospective randomized controlled trial.
     Ann Thorac Surg, 82(3): 1052-6. [Abstract] [Full-text]
114. Ultrasound-guided foam sclerotherapy for the treatment of varicose veins.
     Br J Surg, 93(8): 969-74. [Abstract] [Full-text]
115. Successful treatment of an endodermal sinus tumor of the vagina by chemotherapy alone: a rare case of an infant diagnosed by pathological examination of discharged tumor fragment.
     Pediatr Hematol Oncol, 23(7): 563-9. [Abstract] [Full-text]
116. Phase I clinical trial results of verteporfin enhanced feeder vessel therapy in subfoveal choroidal neovascularisation in age related macular degeneration.
     Br J Ophthalmol, 90(9): 1152-6. [Abstract] [Full-text]
117. Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor?
     Br J Ophthalmol, 90(9): 1168-72. [Abstract] [Full-text]
118. Diet and fluid prescription in stone disease.
     Kidney Int, 70(5): 835-9. [Abstract] [Full-text]
119. Risk factors for photodynamic therapy of predominantly classic choroidal neovascularization in age-related macular degeneration.
     Am J Ophthalmol, 142(3): 441-7. [Abstract] [Full-text]
120. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals.
     Arthritis Rheum, 55(4): 543-50. [Abstract] [Full-text]
121. Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study.
     Invest Ophthalmol Vis Sci, 47(9): 3983-8. [Abstract] [Full-text]
122. Iontophoretic delivery of carboplatin in a murine model of retinoblastoma.
     Invest Ophthalmol Vis Sci, 47(9): 3717-21. [Abstract] [Full-text]
123. Cell adhesion molecules for targeted drug delivery.
     J Pharm Sci, 95(9): 1856-72. [Abstract] [Full-text]
124. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.
     Genes Chromosomes Cancer, 45(10): 933-44. [Abstract] [Full-text]
125. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity.
     J Pharm Sci, 95(9): 1873-87. [Abstract] [Full-text]
126. Safety and efficacy of thrombolytic therapy in postoperative cerebral infarctions.
     Neurol Clin, 24(4): 783-93. [Abstract] [Full-text]
127. In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein.
     Biomaterials, 27(34): 5855-60. [Abstract] [Full-text]
128. Antiretroviral medication errors among hospitalized patients with HIV infection.
     Clin Infect Dis, 43(7): 933-8. [Abstract] [Full-text]
129. Randomized clinical trial assessing the effect of Doppler-optimized fluid management on outcome after elective colorectal resection.
     Br J Surg, 93(9): 1069-76. [Abstract] [Full-text]
130. Between a rock and a hard place: disclosing medical errors.
     Clin Chem, 52(9): 1809-14. [Abstract] [Full-text]
131. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
     Br J Cancer, 95(5): 587-92. [Abstract] [Full-text]
132. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
     Cancer, 107(5): 1093-100. [Abstract] [Full-text]
133. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT.
     Br J Cancer, 95(5): 607-15. [Abstract] [Full-text]
134. Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.
     Cancer, 107(5): 1050-4. [Abstract] [Full-text]
135. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
     Cancer, 107(5): 1014-22. [Abstract] [Full-text]
136. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
     Cancer, 107(5): 967-74. [Abstract] [Full-text]
137. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach.
     Cancer, 107(5): 935-44. [Abstract] [Full-text]
138. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
     J Clin Oncol, 24(25): 4202-8. [Abstract] [Full-text]
139. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
     J Clin Oncol, 24(25): 4163-9. [Abstract] [Full-text]
140. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
     J Clin Oncol, 24(25): 4116-22. [Abstract] [Full-text]
141. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
     J Clin Oncol, 24(25): 4085-91. [Abstract] [Full-text]
142. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
     J Clin Oncol, 24(25): 4069-77. [Abstract] [Full-text]
143. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
     J Clin Oncol, 24(25): 4062-8. [Abstract] [Full-text]
144. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
     J Clin Oncol, 24(25): 4123-8. [Abstract] [Full-text]
145. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
     J Clin Oncol, 24(25): 4143-9. [Abstract] [Full-text]
146. Tandem internal carotid artery/middle cerebral artery occlusion: an independent predictor of poor outcome after systemic thrombolysis.
     Stroke, 37(9): 2301-5. [Abstract] [Full-text]
147. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients.
     Stroke, 37(9): 2288-93. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.